Skip to main content

Drugs Made In America Acquisition Corp.

DMAAU
Exchange
Nasdaq
Industry
Blank Checks
SEC CIK
0002028614

No open-market purchases or sales by Drugs Made In America Acquisition Corp. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $122.3K in total; no superinvestor holds it.

Other share classesDMAADMAAR

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, 0 vs. previous quarter
2
13F valueReported value at the end of Q2 2026
$122.3K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding DMAAU, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding DMAAU at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Drugs Made In America Acquisition Corp. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 18, 2025 (view filing)Feb 18Same dayDrugs Made In America Acquisition LLC10% OwnerPPurchase+30.0K––+0.7%4.19M afterDuplicate filing
Feb 18, 2025 (view filing)Feb 18Same dayDrugs Made In America Acquisition LLC10% OwnerPPurchase+30.0K–––430.0K afterDerivativeDuplicate filing
Feb 18, 2025 (view filing)Feb 18Same dayStockwell LynnCEO and Exe. Chair of BoardPPurchase+30.0K––+0.7%4.19M after
Feb 18, 2025 (view filing)Feb 18Same dayStockwell LynnCEO and Exe. Chair of BoardPPurchase+30.0K–––430.0K afterDerivative
Feb 4, 2025 (view filing)Jan 296 daysLateDrugs Made In America Acquisition LLC10% OwnerPPurchase+400.0K––+4.1%10.3M after
Feb 4, 2025 (view filing)Jan 296 daysLateDrugs Made In America Acquisition LLC10% OwnerSSale−5.70M––−57.8%4.16M afterDuplicate filing
Feb 4, 2025 (view filing)Jan 296 daysLateDrugs Made In America Acquisition LLC10% OwnerPPurchase+400.0K–––400.0K afterDerivativeDuplicate filing
Feb 4, 2025 (view filing)Jan 296 daysLateStockwell LynnCEO and Executive COBPPurchase+400.0K––New position10.3K after
Feb 4, 2025 (view filing)Jan 296 daysLateStockwell LynnCEO and Executive COBSSale−5.70M––−57.8%4.16M after
Feb 4, 2025 (view filing)Jan 296 daysLateStockwell LynnCEO and Executive COBPPurchase+400.0K–––400.0K afterDerivative

Top 10 13F holders, Q2 2026

The largest institutional positions in Drugs Made In America Acquisition Corp. at the end of Q2 2026; share changes are against Q1 2026.

See all 2 holders
Institutions holding DMAAU in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Clear Street Group Inc.10,005$106.2K0.00%+5+0.1%Added
UBS Group AG1,525$16.2K0.00%+4+0.3%Added